Apellis Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $199,685 | $172,325 | $146,377 | $99,182 |
Gross Profit | 176,136 | 151,672 | 126,465 | 76,772 |
EBITDA | -28,994 | -61,646 | -84,028 | -148,297 |
EBIT | -29,443 | -62,090 | -84,518 | -148,702 |
Net Income | -37,657 | -66,423 | -88,576 | -140,237 |
Net Change In Cash | 199,685 | 172,325 | 146,377 | 99,182 |
Free Cash Flow | -8,429 | -133,276 | -97,970 | -169,132 |
Cash | 361,426 | 327,026 | 352,299 | 452,414 |
Basic Shares | 123,904 | 122,957 | 121,232 | 120,292 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $396,591 | $75,422 | $66,563 | $250,646 |
Gross Profit | 336,377 | 69,786 | 61,363 | 225,596 |
EBITDA | -515,417 | -584,500 | -533,005 | -209,426 |
EBIT | -517,121 | -585,987 | -534,497 | -210,285 |
Net Income | -528,628 | -652,172 | -746,354 | -344,874 |
Net Change In Cash | 396,591 | 75,422 | 66,563 | 250,646 |
Free Cash Flow | -595,508 | -515,269 | -564,229 | -165,910 |
Cash | 352,299 | 551,801 | 640,192 | 565,779 |
Basic Shares | 118,678 | 106,114 | 84,421 | 75,163 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$0.28 |
2024-03-31 | -$0.42 |
2023-12-31 | -$0.73 |
2023-09-30 | -$1.17 |
